Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm

D Perkins; J Sarris; S Rossell; Y Bonomo; D Forbes; C Davey; D Hoyer; C Loo; G Murray; S Hood; V Schubert; NL Galvão-Coelho; M O’Donnell; O Carter; P Liknaitzky; M Williams; D Siskind; D Penington; M Berk; D Castle

Journal article

Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm

D Perkins, J Sarris, S Rossell, Y Bonomo, D Forbes, C Davey, D Hoyer, C Loo, G Murray, S Hood, V Schubert, NL Galvão-Coelho, M O’Donnell, O Carter, P Liknaitzky, M Williams, D Siskind, D Penington, M Berk, D Castle

Australian and New Zealand Journal of Psychiatry | SAGE PUBLICATIONS LTD | Published : 2021

DOI: 10.1177/0004867421998785

Abstract

The medical use of psychedelic substances (e.g. psilocybin, ayahuasca, lysergic acid diethylamide and 3,4-methylenedioxymethamphetamine) is attracting renewed interest, driven by a pressing need for research and development of novel therapies for psychiatric disorders, as well as promising results of contemporary studies. In this Viewpoint, we reflect upon the ‘Clinical Memorandum on Psychedelics’ recently released by the Royal Australian and New Zealand College of Psychiatrists and note subsequent developments including the application for down-scheduling of psilocybin and 3,4-methylenedioxymethamphetamine presently being considered by the Therapeutic Goods Administration and approvals for ..

View full abstract

University of Melbourne Researchers

Daniel Perkins Author

Jerome Sarris Author

Yvonne Bonomo Author

David Forbes Author

Related Projects (1)

A RANDOMISED CONTROLLED TRIAL OF LOW-DOSE KETAMINE IN YOUTH WITH SEVERE DEPRESSION AND ELEVATED SUICIDE RISK

Recent research has shown that a single injection of low-dose ketamine has powerful, though short-lived, antidepressant effects. Effective t..

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: D.P., O.C., D.S. and D.H. have no conflicts to declare. N.L.G.-C. is supported by CAPES Foundation from Brazilian Ministry of Education (Research Fellowship 88887.466701/2019-00) and J.S. is supported by an NHMRC Clinical (Fellowship APP1125000). M.B. is supported by a NHMRC Senior Principal Research Fellowship (1059660 and 1156072). S.R. is supported by a NHMRC Senior Research Fellowship (GNT1154651). C.L. has received NHMRC funding for a clinical trial of ketamine in depression (1105089). C.D. is supported by an NHMRC Career Development Fellowship (1141738) and has received NHMRC funding for a clinical trial of ketamine in depression (1138736). M.W. is Executive Director of DGR-1 Health Promotion charity, Psychedelic Research in Science & Medicine Ltd. P.L. is a member of the Medical Advisory Board of Incannex Healthcare Limited.